Richard E. Pratley

Active 1992–2026

249
Papers
58,317
Citations
121
h-index
240
i10-index

Citations

Citations per year for Richard E. Pratley1969: 1 citations1986: 1 citations1990: 1 citations1993: 1 citations1994: 9 citations1995: 22 citations1996: 65 citations1997: 127 citations1998: 142 citations1999: 128 citations2000: 224 citations2001: 233 citations2002: 282 citations2003: 430 citations2004: 409 citations2005: 411 citations2006: 388 citations2007: 356 citations2008: 326 citations2009: 316 citations2010: 272 citations2011: 310 citations2012: 276 citations2013: 301 citations2014: 279 citations2015: 292 citations2016: 229 citations2017: 214 citations2018: 241 citations2019: 886 citations2020: 955 citations2021: 1,289 citations2022: 1,233 citations2023: 1,629 citations2024: 4,197 citations2025: 2,222 citations2026: 85 citations1970–1985: no citations, so these years are not shown1987–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,028 citing papers, 25.2% of this breakdownChina: 1,791 citing papers, 7.5% of this breakdownUnited Kingdom: 1,697 citing papers, 7.1% of this breakdownItaly: 1,230 citing papers, 5.1% of this breakdownCanada: 1,015 citing papers, 4.3% of this breakdownGermany: 981 citing papers, 4.1% of this breakdownAustralia: 809 citing papers, 3.4% of this breakdownDenmark: 690 citing papers, 2.9% of this breakdownSpain: 644 citing papers, 2.7% of this breakdownJapan: 623 citing papers, 2.6% of this breakdownSweden: 591 citing papers, 2.5% of this breakdownFrance: 579 citing papers, 2.4% of this breakdown
0%25.2%Other 30.2%

Fields

  • Medicine75.2%
  • Biochemistry, Genetics and Molecular Biology10%
  • Neuroscience8.4%
  • Nursing1.4%
  • Health Professions1.2%
  • Psychology1%
  • Other2.8%

Topics

  • Diabetes Treatment and Management9.3%
  • Adipokines, Inflammation, and Metabolic Diseases5.3%
  • Diabetes Management and Research4.7%
  • Regulation of Appetite and Obesity4%
  • Pancreatic function and diabetes3.9%
  • Adipose Tissue and Metabolism3.7%
  • Other69.1%

Coauthors

All papers

Open in search
  1. 2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 2,390

  2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

    Authors: , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2021 cited by 1,502

  3. 2. Diagnosis and Classification of Diabetes:Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 1,770

  4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 851

  5. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

    Authors: , , , , , , , , , , , , , - JAMA Cardiology 2020 cited by 1,212

  6. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 777

  7. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 1,496

  8. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 627

  9. 6. Glycemic Targets: Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 683

  10. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 463

  11. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

    Authors: , , , , , , - The Lancet Diabetes & Endocrinology 2018 cited by 764

  12. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 413

  13. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

    Authors: , , , , , , , , - The Lancet 2019 cited by 583

  14. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 444

  15. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

    Authors: , - Frontiers in Endocrinology 2020 cited by 382

  16. 7. Diabetes Technology: Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 266

  17. 15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 280

  18. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 372

  19. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024

    Authors: , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 255

  20. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cyrus Desouza, Thomas Donner, Ken Eliasson, Jan W. Eriksson, Steven Folkerth, Kristy Forshaw, Hans Frandsen, Elena Frolova, Winston Gandy, G Gatipon, Albina Golovach, L. Gonzalez-Orozco, Janusz Gumprecht, Élie Haddad, Troels Krarup Hansen, Thomas C. Hart, Syed Shahzad Hasan, Brent Hella, Simon Heller, Margareta Hellgren, Mark I. Hewitt, S Hietaniemi, Marc‐Phillip Hitz, P Houser, Raphael E. Huntley, R. A. JACKSON, Poul Erik Jakobsen, Anuj Pal Kapoor, L. Kargina, Elena Kazakova, Khalid Khan, E. Klein, H Knoble, N Krasnopeeva, Andre Krzeminski, М. А. Куницына, J Lawhead, Klaus Levin, Philip Levin, Lorena Lewy-Alterbaum, Stina Lindmark, Robert S. Lindsay, Alain Luts, Tatyana Lysenko, Sten Madsbad, Tyler Maxwell, Caroline Mbogua, JA McKnight, Kaj Metsärinne, Т. А. Милованова, Emily Morawski, Ofri Mosenzon, Dan Nabriski, Hai Quy Tram Nguyen, Philip Nicol, Sanna Nieminen, Anita Schwab Nikkola, Paul Norwood, Peter H. O’Donnell, A. Ola Odugbesan, Jeremy C. Parker, Y. Pergaeva, А. Б. Песков, S. Plevin, Joe Pouzar, Richard E. Pratley, Josh Reed, Peter Rossing, Thozhukat Sathyapalan, M. Sergeeva-Kondrachenko and 16 more - The Lancet Diabetes & Endocrinology 2019 cited by 342

  21. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024

    Authors: , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 cited by 189

  22. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2020 cited by 353

  23. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 241

  24. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023

    Authors: , , , , , , , , , , , , , , , , , , , - Diabetes Care 2022 cited by 283